Targeted Diagnostics Aldatu Biosciences specializes in adaptive PCR diagnostics with a focus on viral genetic diversity and accessibility in low- and middle-income countries, presenting an opportunity to position complementary market-entry partnerships, distribution deals, or joint development for affordable tests in resource-limited settings.

Non-Dilutive Funding With over 20 million in non-dilutive NIH funding and a track record of SBIR grants, there is potential to engage in co-development or grant-aligned programs, offering investors and partners a clear path to funded collaboration and risk-sharing in diagnostic innovation.

Quality & Compliance ISO 13485 certified quality management suggests reliability for commercial-scale diagnostics and potential for contract manufacturing, distribution partnerships, and regulatory-ready product launches in global markets.

Recent Growth Signals Past public financing milestones, including SBIR grants and ongoing COVID-19 test development activity, indicate a proven ability to secure capital and respond quickly to emerging infectious disease needs, opening doors for fast-track collaboration opportunities and joint go-to-market initiatives.

Strategic Fit Markets Target markets include epidemic preparedness and global health where robust, accessible diagnostics are prioritized; there is scope to pursue partnerships with public health agencies, NGOs, and regional distributors serving LMICs, leveraging their networks and Aldatu’s PANDAA platform for broad pathogen detection.